Form 4: Quest Diagnostics EVP Sells Shares in Routine Transactions

Quest Diagnostics' EVP of Regional Businesses, Catherine T. Doherty, reported sales of common stock totaling 1,280 shares for tax obligations and pursuant to a 10b5-1 plan.

Summary

• Catherine T. Doherty, EVP, Regional Businesses at Quest Diagnostics Inc. (DGX), reported transactions involving the company's common stock.
• On March 2, 2026, Doherty disposed of 648 shares of common stock at a price of $204.86 per share. This sale was conducted to satisfy tax obligations arising from the vesting of previously granted restricted share units.
• On March 3, 2026, an additional 632 shares of common stock were disposed of at a price of $207.73 per share. This transaction was executed under a pre-arranged Rule 10b5-1 sales plan.
• Following these transactions, Doherty directly beneficially owns 67,754 shares of common stock.
• Additionally, Doherty indirectly beneficially owns 4,502 shares through the Company's tax-qualified Profit Sharing (401(k)) Plan, with these shares acquired periodically by the plan trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider sales for tax purposes and under a pre-arranged plan, which typically do not indicate a significant shift in company prospects or executive sentiment.

Positives

• The sale under a Rule 10b5-1 plan indicates a pre-scheduled transaction, reducing concerns about opportunistic selling.
• A portion of the sale was to cover tax obligations from RSU vesting, which is a routine event for executives.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those for tax obligations or executed under pre-arranged 10b5-1 plans, are common occurrences in the healthcare diagnostics industry and generally do not signal a change in management's outlook on the company's fundamentals. These transactions are often part of an executive's long-term financial planning and compensation structure.

Comparison to Industry Standards

• These types of insider transactions are standard practice across publicly traded companies, including those in the healthcare sector like Laboratory Corporation of America Holdings (LH) or Eurofins Scientific (ERF.PA), where executives frequently sell shares to cover tax liabilities from equity awards or diversify holdings through 10b5-1 plans. The reported sales volume relative to the executive's total holdings appears routine.

Related Party Transactions

• The transactions involve an executive of Quest Diagnostics Inc. selling company stock, which is a related party transaction by definition of insider trading.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-planned sales by an executive.
• Employees: No direct impact indicated.
• Customers: No direct impact indicated.
• Suppliers: No direct impact indicated.
• Creditors: No direct impact indicated.

Key Dates

Recommendation

The reported insider sales are routine, involving tax obligations and a pre-arranged 10b5-1 plan. Such transactions are common and generally do not signal a change in the company's fundamental outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment position.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Sale, Catherine T. Doherty, 10b5-1 Plan, Restricted Share Units, Executive Compensation